Merck & Company Inc (MRK)vsRoyalty Pharma Plc (RPRX)
MRK
Merck & Company Inc
$143.93
-0.54%
HEALTHCARE · Cap: $355.10B
RPRX
Royalty Pharma Plc
$58.61
-0.24%
HEALTHCARE · Cap: $36.96B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 2525% more annual revenue ($66.57B vs $2.54B). RPRX leads profitability with a 32.0% profit margin vs 4.8%. RPRX appears more attractively valued with a PEG of 1.49. RPRX earns a higher WallStSmart Score of 57/100 (C).
MRK
Hold36
out of 100
Grade: F
RPRX
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$143.93
$61.09 premium
Margin of Safety
-64.9%
Fair Value
$36.75
Current Price
$58.61
$21.86 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Keeps 32 of every $100 in revenue as profit
16.5% revenue growth
Areas to Watch
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Premium valuation, high expectations priced in
Elevated debt levels
Weak financial health signals
Earnings declined 46.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : RPRX
The strongest argument for RPRX centers on Profit Margin, Revenue Growth. Profitability is solid with margins at 32.0% and operating margin at 19.8%. Revenue growth of 16.5% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : RPRX
The primary concerns for RPRX are P/E Ratio, Debt/Equity, Piotroski F-Score.
Key Dynamics to Monitor
MRK profiles as a value stock while RPRX is a growth play — different risk/reward profiles.
RPRX carries more volatility with a beta of 0.43 — expect wider price swings.
RPRX is growing revenue faster at 16.5% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
RPRX scores higher overall (57/100 vs 36/100), backed by strong 32.0% margins and 16.5% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Royalty Pharma Plc
HEALTHCARE · BIOTECHNOLOGY · USA
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?